Materialise NV announced on November 20, 2025 that its ordinary shares will now trade on the Euronext Brussels exchange in addition to the company’s existing Nasdaq listing of American depositary shares. The dual listing is intended to broaden the company’s European investor base, increase share liquidity, and provide operational flexibility for future initiatives such as share‑buyback programs or the potential issuance of additional American depositary shares. No new shares are being issued and the company is not raising capital through this listing.
In its most recent quarterly report, Materialise reported total revenue of €66.3 million for the third quarter of 2025, a 3.5 % decline year‑over‑year but a 2.2 % increase from the second quarter. The decline was driven by a 17.1 % drop in the Manufacturing segment and a 7.4 % fall in the Software segment, both of which were pressured by supply‑chain constraints and higher input costs. In contrast, the Medical segment grew 10.3 % year‑over‑year to €32.8 million, setting a new quarterly revenue record and underscoring the resilience of the company’s high‑margin medical‑device software business. Adjusted EBIT fell to €2.9 million from €4.4 million in the same quarter last year, largely because the lower‑margin segments weighed on overall profitability, while net profit dropped to €1.8 million from €3.0 million.
The second‑quarter results showed a 5.8 % year‑over‑year revenue decline to €64.8 million, with the Medical segment again leading growth at 16.7 % to €32.9 million. Manufacturing revenue fell 24.9 % and Software revenue fell 12.1 %. Gross profit as a percentage of revenue rose to 58.3 %, reflecting a higher mix of high‑margin medical contracts. Adjusted EBIT improved to €3.1 million, but the company’s net result was a modest €199 k profit. Management revised full‑year revenue guidance downward to €265–280 million from the prior €270–285 million range, citing uncertainty in industrial demand and currency pressures, while reaffirming full‑year adjusted EBIT guidance of €6–10 million, indicating confidence in maintaining profitability through cost discipline.
Founders Fried Vancraen and Hilde Ingelaere have agreed to sell up to 590,000 shares—about 1 % of the company’s outstanding shares—on the Brussels exchange. The sale is a trading arrangement that preserves the founders’ overall ownership stake and does not involve a capital‑raising transaction. The dual listing therefore enhances liquidity without diluting existing shareholders or altering the company’s capital structure.
CEO Brigitte de Vet‑Veithen highlighted that the medical segment remains a key growth engine amid macroeconomic headwinds affecting Manufacturing and Software. She noted that the company has implemented cost‑control measures and continues to invest in research and development, particularly following the July 2024 acquisition of FEops, an AI‑driven simulation technology provider for structural heart interventions.
Materialise’s balance sheet remains robust, with net cash of €67.7 million at the end of Q3 2025 and a credit facility in place to support future capital‑expenditure or acquisition opportunities. The company’s focus on the high‑margin medical segment, combined with disciplined cost management and strategic investments in AI and simulation, positions it to navigate current macro challenges while pursuing long‑term growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.